Eric von Hofe
President bei NUGENEREX IMMUNO-ONCOLOGY, INC.
Profil
Eric von Hofe's current job(s) include Vice President at Generex Biotechnology Corp.
and President & Chief Scientific Officer at NuGenerex Immuno-Oncology, Inc. Dr. von Hofe's former job(s) include Director-Programs & Operations at Millennium Pharmaceuticals, Inc., Director-New Targets at Idera Pharmaceuticals, Inc., Assistant Professor-Pharmacology at the University of Massachusetts, and President & Chief Operating Officer at Affyimmune Therapeutics, Inc. Dr. von Hofe obtained a doctorate degree from the University of Southern California.
Aktive Positionen von Eric von Hofe
Unternehmen | Position | Beginn |
---|---|---|
GENEREX BIOTECHNOLOGY CORPORATION | Corporate Officer/Principal | 01.01.2005 |
NUGENEREX IMMUNO-ONCOLOGY, INC. | President | - |
Ehemalige bekannte Positionen von Eric von Hofe
Unternehmen | Position | Ende |
---|---|---|
Affyimmune Therapeutics, Inc.
Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | President | - |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | - |
University of Massachusetts | Corporate Officer/Principal | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Chief Operating Officer | - |
Ausbildung von Eric von Hofe
University of Southern California | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Generex Biotechnology Corp.
Generex Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Generex Biotechnology Corp. is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. It builds new kind of healthcare company, which provides support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. The company was founded by Rose C. Perri on September 4, 1997 and is headquartered in Miramar, FL. | Health Technology |
NuGenerex Immuno-Oncology, Inc.
NuGenerex Immuno-Oncology, Inc. BiotechnologyHealth Technology NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL. | Health Technology |
Affyimmune Therapeutics, Inc.
Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | Commercial Services |